Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness

Autor segons l'article: Ruiz-Plazas, Xavier; Rodriguez-Gallego, Esther; Alves, Marta; Altuna-Coy, Antonio; Lozano-Bartolome, Javier; Portero-Otin, Manel; Francesc Garcia-Fontgivell, Joan; Martinez-Gonzalez, Salome; Segarra, Jose; Chacon, Matilde R

Departament: Ciències Mèdiques Bàsiques; Medicina i Cirurgia

Autor/s de la URV: Alves Santiago, Marta / Martínez González, María Salomé / Rodríguez Gallego, Esther

Paraules clau: Biofluids; Biomarkers; Biomarkers, tumor; Blood; Body fluids; Cells; Cholesterol; Cohort studies; Cytokine tweak; Diagnosis; Fn14 axis; Force; Humans; Kallikreins; Macrophages; Male; Middle aged; Neoplasm invasiveness; Progression; Prostate cancer; Prostatic neoplasms; Risk; Roc curve; Soluble cd163; Statistics, nonparametric; Stweak; Tnfrsf12a protein, human; Tnfsf12 protein, human; Tweak; Tweak receptor; Tweak/fn14 axis

Resum: Background Conventional clinical biomarkers cannot accurately differentiate indolent from aggressive prostate cancer (PCa). We investigated the usefulness of a biomarker panel measured exclusively in biofluids for assessment of PCa aggressiveness. Methods We collected biofluid samples (plasma/serum/semen/post-prostatic massage urine) from 98 patients that had undergone radical prostatectomy. Clinical biochemistry was performed and several cytokines/chemokines including soluble(s) TWEAK, sFn14, sCD163, sCXCL5 and sCCL7 were quantified by ELISA in selected biofluids. Also, the expression of KLK2, KLK3, Fn14, CD163, CXCR2 and CCR3 was quantified by real-time PCR in semen cell sediment. Univariate, logistic regression, and receiver operating characteristic (ROC) analyses were used to assess the predictive ability of the selected biomarker panel in conjunction with clinical and metabolic variables for the evaluation of PCa aggressiveness. Results Total serum levels of prostate-specific antigen (PSA), semen levels of sTWEAK, fasting glycemia and mRNA levels of Fn14, KLK2, CXCR2 and CCR3 in semen cell sediment constituted a panel of markers that was significantly different between patients with less aggressive tumors [International Society of Urological Pathology (ISUP) grade I and II] and those with more aggressive tumors (ISUP grade III, IV and V). ROC curve analysis showed that this panel could be used to correctly classify tumor aggressiveness in 90.9% of patients. Area under the curve (AUC) analysis revealed that this combination was more accurate [AUC = 0.913 95% confidence interval (CI) 0.782-1] than a classical non-invasive selected clinical panel comprising age, tumor clinical stage (T-classification) and total serum PSA (AUC = 0.721 95% CI 0.613-0.830). Conclusions TWEAK/Fn14 axis in combination with a selected non-invasive biomarker panel, including conventional clinical biochemistry, can improve the predictive power of serum PSA levels and could be used to classify PCa aggressiveness.

Àrees temàtiques: Biochemistry, genetics and molecular biology (all); Biochemistry, genetics and molecular biology (miscellaneous); Biotecnología; Ciências biológicas i; Ciências biológicas ii; Ciências biológicas iii; Farmacia; General biochemistry,genetics and molecular biology; General medicine; Interdisciplinar; Medicina i; Medicina ii; Medicina iii; Medicina veterinaria; Medicine (all); Medicine (miscellaneous); Medicine, research & experimental; Nutrição; Odontología

Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/

Adreça de correu electrònic de l'autor: esther.rodriguez@urv.cat; marta.alves@estudiants.urv.cat; mariasalome.martinez@urv.cat

Data d'alta del registre: 2025-03-03

Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion

Enllaç font original: https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-019-2053-6

Referència a l'article segons font original: Journal Of Translational Medicine. 17 (1): 307-

Referència de l'ítem segons les normes APA: Ruiz-Plazas, Xavier; Rodriguez-Gallego, Esther; Alves, Marta; Altuna-Coy, Antonio; Lozano-Bartolome, Javier; Portero-Otin, Manel; Francesc Garcia-Font (2019). Biofluid quantification of TWEAK/Fn14 axis in combination with a selected biomarker panel improves assessment of prostate cancer aggressiveness. Journal Of Translational Medicine, 17(1), -. DOI: 10.1186/s12967-019-2053-6

URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/

DOI de l'article: 10.1186/s12967-019-2053-6

Entitat: Universitat Rovira i Virgili

Any de publicació de la revista: 2019

Tipus de publicació: Journal Publications